Experiencing the MiniMed 670G System after 43 Years with Diabetes

Experiencing the MiniMed 670G System after 43 Years with Diabetes

In March, we shipped the MiniMed 670G systems to customers in the Customer Training Phase. Among them is Laura, Medtronic Clinical Specialist in Phoenix, Arizona, who has been a part of the Medtronic family – both as a Certified Product Trainer and employee – for 26 years. Today, she shares her experience with the new system.

I’ve been on the MiniMed 670G system for a month, and haven’t felt this good in 43 years living with diabetes. I love it!

When the FDA approved the MiniMed 670G system, I cried tears of joy. I couldn’t believe this day had finally come.

Insulin pumps and continuous glucose monitors (CGM) are a huge part of my personal and professional life. Watching and personally experiencing the advancements in pump and sensor technology has been amazing. My first insulin pump in 1980 weighed a whopping 2.7 pounds (in comparison, the MiniMed 670G system is 1/5 pound)!

After 43 years of living with diabetes and 37 years pumping, I’m ecstatic to be on this journey with the world’s first hybrid closed loop system – the MiniMed 670G system!

I live an active lifestyle, and no day is the same. For people with diabetes, this means insulin needs vary each day. I love that the MiniMed 670G system understands this – getting to know my insulin needs more every day, and automatically adjusts and personalizes insulin delivery 24 hours a day.

I’ve struggled with hypoglycemia unawareness for many years, and the new Suspend before low feature – to me – is a miracle! Suspend before low kept me from going low four times in the three days before I turned on Auto Mode. I didn’t even know I was about to have any lows until I looked at my CareLink report! Starting my day off right and spending more time in range allows me to have more energy and be more productive.

With Auto Mode, I’m avoiding lows almost all together and am in my target range 80-90% of the time. Increased automated allows me to spend less time managing my diabetes and more time sleeping uninterrupted or going about my day. I can’t tell you how excited this makes me! With the new system, I feel safer sleeping, driving, traveling, and in everything I do. My husband worries less at night or when one of us is out of town, when he’s most concerned about hypoglycemic events.

The thing I’m most excited about is the impact the MiniMed 670G system will have on everyone affected by type 1 diabetes. This technology is something my family only hoped would come to fruition one day. I wish my parents were here to see it; they would be happy and relieved to know their daughter is able to better manage her diabetes and have more peace of mind with this technology.

I can hardly wait to deliver this truly groundbreaking innovation to the patients and healthcare providers I work with daily, and show them what increased automation in an insulin pump can do to improve the lives of people with type 1 diabetes.

Important Safety Information

The Medtronic MiniMed 670G system requires a prescription and is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G System includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values.

The Guardian Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).

WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

 Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Do not use the serter on products other than the Enlite sensor or Guardian Sensor (3). Medtronic cannot guarantee the safety or efficacy of this product if used with other products. The reservoir is contraindicated for the infusion of blood or blood products.

Infusion sets are indicated for subcutaneous use only and not for intravenous (IV) infusion or the infusion of blood or blood products. Insulin pump therapy is not recommended for those who are unwilling to perform at least four blood glucose tests per day. As insulin pumps use rapid acting insulin only, BG testing is required to help identify rapid glycemic deterioration due to insulin infusion occlusion, infusion site problems, insulin stability issues, user error, or a combination of these. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional.

The safety of the 670G system has not been studied in people with impaired kidney function. Please let your healthcare professional know if you have kidney disease so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks. The safety of the 670G system has not been studied in pregnant women, people with type 2 diabetes, or in people using other anti-hyperglycemic therapies apart from insulin. Please let your healthcare professional know if any of these conditions apply to you so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks.

For complete safety information, please consult the appropriate User Guide.

Print This Post Print This Post
Tags: , , , , ,
Latest Comments
  1. Kendall Smith
  2. Steve
  3. susan
    • Sara Tilleskjor Sara Tilleskjor
      • Rochelle
        • Gisela Pedroza
  4. Margaret Hickman
    • Danielle Swanson
      • Margaret Hickman
        • Andrew
  5. Bry
    • Danielle Swanson
      • Andrew
  6. Howard L RICHARDSON
    • Danielle Swanson
      • Andrew
  7. Lanita "Kay" Wagner
  8. Stephanie
  9. GUGLIELMO FERRERO VARSINO
    • Yuri Treminio

Post A Comment

Your email address will not be published. Required fields are marked *